Thursday, October 12, 2017 8:06:56 PM
Analyst Jim Birchenough is bullish on the company following selection of IPI-549 monotherapy data as a late breaker oral presentation at SITC annual meeting next month. The analyst comments "Based on prior SITC late breaker data we see a reasonable likelihood of proof-of-concept response rate data, and with likely validation of tumor macrophage targeting in immunooncology (IO) and a unique mechanism of action we see upside potential not reflected at current stock price."
New York Yankees and Duke Basketball
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM